Alaunos Therapeutics Overview
- Year Founded
-
1998
- Status
-
Public
- Employees
-
34
- Stock Symbol
-
TCRT
- Investments
-
2
- Share Price
-
$4.00
- (As of Monday Closing)
Alaunos Therapeutics General Information
Description
Alaunos Therapeutics Inc is a clinical-stage cellular immuno-oncology company dedicated to the treatment of solid tumors through adoptive TCR-T cell therapy. It strikes cancer at its core by engineering cell therapies that target Neoantigens arising from genomic mutations. It has a single reportable and operating segment related to biopharmaceutical research and development.
Contact Information
Website
www.alaunos.comCorporate Office
- 2617 Bissonnet Street
- Suite 225
- Houston, TX 77005
- United States
Corporate Office
- 2617 Bissonnet Street
- Suite 225
- Houston, TX 77005
- United States
Alaunos Therapeutics Stock Performance
As of 14-Jul-2025, Alaunos Therapeutics’s stock price is $4.00. Its current market cap is $7.91M with 1.98M shares.
(As of Monday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $4.00 | $4.99 | $1.31 - $6.80 | $7.91M | 1.98M | 36.7K | -$2.54 |
Alaunos Therapeutics Financials Summary
As of 31-Mar-2025, Alaunos Therapeutics has a trailing 12-month revenue of $10K.
|
In Thousands, USD |
TTM 31-Mar-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 |
|---|---|---|---|---|
| EV | 1,263 | 1,367 | 6,239 | 143,788 |
| Revenue | 10 | 10 | 5 | 2,922 |
| EBITDA | (4,071) | (4,677) | (30,904) | (31,817) |
| Net Income | (4,071) | (4,679) | (35,140) | (37,730) |
| Total Assets | 2,120 | 2,755 | 8,263 | 64,937 |
| Total Debt | 0 | 0 | 19,511 |
Alaunos Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Alaunos Therapeutics Comparisons
Industry
Financing
Details
Alaunos Therapeutics Competitors (40)
One of Alaunos Therapeutics’s 40 competitors is Affini-T, a Venture Capital-Backed company based in Watertown, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Affini-T | Venture Capital-Backed | Watertown, MA | ||||
| Biogen | Formerly VC-backed | Cambridge, MA | ||||
| Agenus | Formerly VC-backed | Lexington, MA | ||||
| ImmunityBio | Formerly VC-backed | San Diego, CA | ||||
| Iovance Biotherapeutics | Corporation | San Carlos, CA |
Alaunos Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Alaunos Therapeutics Patents
Alaunos Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20250216381-A1 | Methods for identifying neoantigen-reactive t cell receptors | Pending | 21-Mar-2022 | ||
| US-20250145950-A1 | Methods for activation and expansion of t cells | Pending | 01-Feb-2022 | ||
| AU-2022227085-A1 | Recombinant vectors comprising polycistronic expression cassettes and methods of use thereof | Pending | 25-Feb-2021 | ||
| CA-3209732-A1 | Recombinant vectors comprising polycistronic expression cassettes and methods of use thereof | Pending | 25-Feb-2021 | ||
| EP-4298121-A1 | Recombinant vectors comprising polycistronic expression cassettes and methods of use thereof | Pending | 25-Feb-2021 | C07K14/5443 |
Alaunos Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Alaunos Therapeutics Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Alaunos Therapeutics Investments & Acquisitions (2)
Alaunos Therapeutics’s most recent deal was a Joint Venture with Eden BioCell. The deal was made on 18-Dec-2018.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Eden BioCell | 18-Dec-2018 | Joint Venture | Drug Delivery | ||
| EasyWeb | 13-Sep-2005 | Merger/Acquisition | Media and Information Services (B2B) |
Alaunos Therapeutics ESG
Risk Overview
Risk Rating
Updated April, 01, 2022
31.17 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 14,912
Rank
Percentile
Pharmaceuticals
Industry
of 965
Rank
Percentile
Biotechnology
Subindustry
of 443
Rank
Percentile
Alaunos Therapeutics FAQs
-
When was Alaunos Therapeutics founded?
Alaunos Therapeutics was founded in 1998.
-
Where is Alaunos Therapeutics headquartered?
Alaunos Therapeutics is headquartered in Houston, TX.
-
What is the size of Alaunos Therapeutics?
Alaunos Therapeutics has 34 total employees.
-
What industry is Alaunos Therapeutics in?
Alaunos Therapeutics’s primary industry is Biotechnology.
-
Is Alaunos Therapeutics a private or public company?
Alaunos Therapeutics is a Public company.
-
What is Alaunos Therapeutics’s stock symbol?
The ticker symbol for Alaunos Therapeutics is TCRT.
-
What is the current stock price of Alaunos Therapeutics?
As of 14-Jul-2025 the stock price of Alaunos Therapeutics is $4.00.
-
What is the current market cap of Alaunos Therapeutics?
The current market capitalization of Alaunos Therapeutics is $7.91M.
-
What is Alaunos Therapeutics’s current revenue?
The trailing twelve month revenue for Alaunos Therapeutics is $10K.
-
Who are Alaunos Therapeutics’s competitors?
Affini-T, Biogen, Agenus, ImmunityBio, and Iovance Biotherapeutics are some of the 40 competitors of Alaunos Therapeutics.
-
What is Alaunos Therapeutics’s annual earnings per share (EPS)?
Alaunos Therapeutics’s EPS for 12 months was -$2.54.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
